Clinical trial results suggest no benefit of adding immunotherapy to platinum-based therapies for treating TKI-resistant metastatic NSCLC (15–18), with the exception of a small subgroup analysis of patients with EGFR-mutated NSCLC and prior TKI exposure who received atezolizumab added to a bevacizumab-carboplatin-paclitaxel regimen (19), a regimen that nonetheless did not garner US regulatory approval. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.